Other clinical trials investigating OLA in the adjuvant setting include the SUBITO (Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer trial; NCT02810743) sponsored by NKI, Netherlands. This evidence concerns the gene BRCA1 and breast carcinoma.